IRIS
BILO', Maria Beatrice
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 11.874
AS - Asia 3.804
EU - Europa 3.368
SA - Sud America 659
Continente sconosciuto - Info sul continente non disponibili 307
AF - Africa 128
OC - Oceania 10
Totale 20.150
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 11.688
SG - Singapore 1.540
RU - Federazione Russa 797
VN - Vietnam 711
IT - Italia 630
HK - Hong Kong 568
BR - Brasile 485
CN - Cina 428
IE - Irlanda 425
DE - Germania 275
FR - Francia 270
SE - Svezia 264
UA - Ucraina 220
GB - Regno Unito 152
IN - India 134
BD - Bangladesh 104
FI - Finlandia 90
CA - Canada 77
AR - Argentina 61
MX - Messico 57
NL - Olanda 49
ES - Italia 46
PL - Polonia 45
JP - Giappone 42
IQ - Iraq 41
ZA - Sudafrica 34
CI - Costa d'Avorio 30
TR - Turchia 29
VE - Venezuela 26
AT - Austria 25
CO - Colombia 23
PK - Pakistan 23
BE - Belgio 21
UZ - Uzbekistan 21
EC - Ecuador 20
MA - Marocco 20
PH - Filippine 19
SA - Arabia Saudita 19
PY - Paraguay 15
TH - Thailandia 14
ID - Indonesia 11
LT - Lituania 11
AE - Emirati Arabi Uniti 10
DZ - Algeria 10
CL - Cile 9
JM - Giamaica 9
JO - Giordania 9
KR - Corea 9
AU - Australia 8
CR - Costa Rica 8
MY - Malesia 8
TN - Tunisia 8
TW - Taiwan 8
AZ - Azerbaigian 7
BO - Bolivia 7
EG - Egitto 7
HN - Honduras 7
IL - Israele 7
KE - Kenya 6
LB - Libano 6
KZ - Kazakistan 5
OM - Oman 5
PS - Palestinian Territory 5
RS - Serbia 5
TT - Trinidad e Tobago 5
UY - Uruguay 5
AL - Albania 4
CZ - Repubblica Ceca 4
DK - Danimarca 4
NG - Nigeria 4
NP - Nepal 4
PE - Perù 4
PR - Porto Rico 4
RO - Romania 4
AM - Armenia 3
BG - Bulgaria 3
CH - Svizzera 3
GR - Grecia 3
GT - Guatemala 3
HU - Ungheria 3
PA - Panama 3
BH - Bahrain 2
DM - Dominica 2
DO - Repubblica Dominicana 2
EE - Estonia 2
GD - Grenada 2
GE - Georgia 2
GY - Guiana 2
HR - Croazia 2
KG - Kirghizistan 2
LY - Libia 2
MD - Moldavia 2
MN - Mongolia 2
NI - Nicaragua 2
PT - Portogallo 2
SK - Slovacchia (Repubblica Slovacca) 2
SN - Senegal 2
SR - Suriname 2
SV - El Salvador 2
BA - Bosnia-Erzegovina 1
Totale 19.823
Salva come PNG Salva come JPEG
Città #
Des Moines 1.774
Ashburn 1.445
Singapore 1.125
Chandler 1.018
San Jose 690
Hong Kong 556
Fairfield 535
Dallas 515
Jacksonville 461
Dublin 423
Houston 339
Council Bluffs 323
Boardman 278
Wilmington 250
Woodbridge 249
Ho Chi Minh City 234
Seattle 222
Cambridge 216
The Dalles 179
Hanoi 173
Lawrence 164
Princeton 163
Lauterbourg 157
New York 152
Los Angeles 151
San Mateo 142
Ann Arbor 123
Moscow 111
Beijing 108
Redmond 88
Milan 85
Santa Clara 71
San Diego 66
Helsinki 62
Washington 62
Chicago 56
Munich 52
Pune 51
Orem 48
São Paulo 46
Da Nang 38
London 36
Tokyo 35
Hefei 34
Phoenix 34
San Francisco 34
Warsaw 32
Abidjan 30
Frankfurt am Main 29
Montreal 29
Nuremberg 29
Buffalo 28
Rome 27
Stockholm 27
Turku 26
Chennai 25
Columbus 25
Miano 23
Atlanta 22
Denver 21
Haiphong 21
Manchester 21
Mexico City 21
Ancona 20
Brooklyn 20
Centro 20
Salt Lake City 20
Amsterdam 19
Tashkent 19
Boston 18
Baghdad 16
Brussels 16
Shanghai 16
Guangzhou 15
Toronto 15
Florence 14
Falls Church 13
Kilburn 13
Mumbai 13
Norwalk 13
Cedar Knolls 12
Johannesburg 12
Charlotte 11
Hải Dương 11
Miami 11
Riyadh 11
Brasília 10
Madrid 10
Shenzhen 10
St Petersburg 10
Tampa 10
Can Tho 9
Naples 9
New Delhi 9
Querétaro 9
Rio de Janeiro 9
Wuhan 9
Amman 8
Ankara 8
Belo Horizonte 8
Totale 14.086
Salva come PNG Salva come JPEG
Nome #
Contraindications to immunotherapy: A global approach 433
Anaphylaxis in Elderly Patients-Data From the European Anaphylaxis Registry 284
The roadmap for the Allergology specialty and allergy care in Europe and adjacent countries. An EAACI position paper 259
Idiopathic anaphylaxis 258
Insights from comparison of serum IgG4 between T2-eosinophilic asthma and eosinophilic granulomatosis with polyangiitis/idiopathic hypereosinophilic syndrome 257
Anaphylaxis 193
ANCA-negative EGPA: only eosinophils without vasculitis? Insights from anti-T2 biologics 191
Diagnosing, managing and preventing anaphylaxis: Systematic review 186
Rhinopharyngoscopy, computed tomography and magnetic resonance imaging 176
Cabbage and fermented vegetables: From death rate heterogeneity in countries to candidates for mitigation strategies of severe COVID-19 168
Anaphylaxis to baobab fruit: The paradox of “natural healthy food” 164
Safety and Adherence to Venom Immunotherapy During COVID-19 Pandemic 162
Clinical aspects of hymenoptera venom allergy and venom immunotherapy 160
Basal Tryptase High Levels Associated with a History of Arterial Hypertension and Hypercholesterolemia Represent Risk Factors for Severe Anaphylaxis in Hymenoptera Venom-Allergic Subjects over 50 Years Old 160
EAACI Molecular Allergology User's Guide 156
Development of a model care pathway for the management of Hymenoptera venom allergy: Evidence-based key interventions and indicators 156
Hymenoptera Venom Allergy: Management of children and adults in clinical practice 152
Forced oscillation technique as method to document and monitor the efficacy of mepolizumab in treating severe eosinophilic asthma 151
Anaphylactic Reactions After Discontinuation of Hymenoptera Venom Immunotherapy: A Clonal Mast Cell Disorder Should Be Suspected 147
Unmet needs and relationship between general practitioners (GPs) and allergists living in Campania region (southern Italy) 147
EAACI guidelines: Anaphylaxis (2021 update) 147
Diagnosis of Immediate-Type ß-Lactam Allergy In Vitro by Flow-Cytometric Basophil Activation Test and Sulfi doleukotriene Production: a Multicenter Study. 145
Anaphylaxis in children and adolescents: The European Anaphylaxis Registry 145
Fatal anaphylaxis in Italy: Analysis of cause-of-death national data, 2004-2016 144
Sensitization to Cat: Why Not Use Molecular Diagnostics instead of the Nasal Challenge in Clinical Practice? 144
CAP-Inhibition, Molecular Diagnostics, and Total IgE in the Evaluation of Polistes and Vespula Double Sensitization 143
European hornet (Vespa crabro) sting: a new risk factor for life-threatening reaction in hymenoptera allergic patients? 142
Allergen immunotherapy for insect venom allergy: protocol for a systematic review 141
Advances in Hymenoptera venom immunotherapy 140
In vivo diagnosis of allergic diseases - allergen provocation tests 139
Efficacy of an air‐cleaning device equipped with a high efficiency particulate air filter in house dust mite respiratory allergy 138
Precision Medicine in Hymenoptera Venom Allergy: Diagnostics, Biomarkers, and Therapy of Different Endotypes and Phenotypes 138
Secondary prevention measures in anaphylaxis patients: Data from the anaphylaxis registry 137
Epidemiology of hymenoptera allergy 137
Detection of Gibberellin-Regulated Protein (Peamaclein) Sensitization among Italian Cypress Pollen-Sensitized Patients 137
Is diet partly responsible for differences in COVID-19 death rates between and within countries? 137
Why are allergens not detected in the bronchoalveolar lavage fluid of patients undergoing fiberoptic bronchoscopy? Possible explanations 136
Large local reactions to Hymenoptera stings: outcome of re-stings in real-life 135
Allergen immunotherapy for insect venom allergy: a systematic review and meta-analysis 134
Risk Factors and Characteristics of Biphasic Anaphylaxis 134
The role of component-resolved diagnosis in Hymenoptera venom allergy 133
Anaphylaxis caused by Hymenoptera stings: from epidemiology to treatment 131
Shedding Light on the Venom Proteomes of the Allergy-Relevant Hymenoptera Polistes dominula (European Paper Wasp) and Vespula spp. (Yellow Jacket) 130
A prevalent exposure to male dog is a risk factor for exclusive allergic sensitization to Can f 5: An Italian multicenter study 130
Diagnosis of Hymenoptera venom allergy 130
Safety of a 2-day ultrarush immunotherapy in vespid allergic patients: Focus on elevated serum tryptase 129
Allergen-specific immunotherapy provides immediate, long-term and preventive clinical effects in children and adults: the effects of immunotherapy can be categorised by level of benefit -the centenary of allergen specific subcutaneous immunotherapy 129
Antigen 5 Allergens of Hymenoptera Venoms and Their Role in Diagnosis and Therapy of Venom Allergy 129
Phenotype and risk factors of venom-induced anaphylaxis: a case-control study of the European Anaphylaxis Registry 128
Prevention and treatment of hymenoptera venom allergy: Guidelines for clinical practice 128
World Allergy Organization Guidelines for the Assessment and Management of Anaphylaxis 127
Shortness of interval between two stings as risk factor for developing Hymenoptera venom allergy 127
Severe asthma in adults does not significantly affect the outcome of COVID-19 disease: Results from the Italian Severe Asthma Registry 126
Oxytocin: a likely underestimated risk for anaphylactic reactions in delivering women sensitized to latex 125
Allergy immunotherapy across the life cycle to promote active and healthy ageing: from research to policies 124
Editorial: Anaphylaxis – A Distinct Immunological Syndrome, but How Much Do We Really Understand? 123
Allergy to stings and bites from rare or locally important arthropods: Worldwide distribution, available diagnostics and treatment 121
Omalizumab in chronic spontaneous urticaria: patient-tailored tapering or planned discontinuation? 121
World Allergy Organization survey on global availability of essentials for the assessment and management of anaphylaxis by allergy-immunology specialists in health care settings 121
Bonifazi F. Epidemiology of Hymenoptera sting anaphylaxis 121
Replacement and Immunomodulatory Activities of 20% Subcutaneous Immunoglobulin Treatment: A Single-Center Retrospective Study in Autoimmune Myositis and CVID Patients 121
Nomenclature of allergic diseases and hypersensitivity reactions: Adapted to modern needs: An EAACI position paper 120
Skin test concentrations for systemically administered drugs -- an ENDA/EAACI Drug Allergy Interest Group position paper 118
Common Variable Immunodeficiency in Elderly Patients: A Long-Term Clinical Experience 118
Allergies and COVID-19 vaccines: An ENDA/EAACI Position paper 118
EAACI anaphylaxis guidelines: Systematic review protocol 117
Immunotherapy for hymenoptera venom allergy: too expensive for European health care? 117
2012 Update: World Allergy Organization Guidelines for the assessment and management of anaphylaxis 116
Tolerability of three selective cyclo-oxygenase-2 inhibitors, meloxicam, celecoxib and rofecoxib in NSAID-sensitive patients 116
Honeybee venom immunotherapy: a comparative study using purified and nonpurified aqueous extracts in patients with normal Basal serum tryptase concentrations 115
Predictors of side effects during the buildup phase of venom immunotherapy for Hymenoptera venom allergy: the importance of baseline serum tryptase 114
Efficacy of a single dose of omalizumab for the prevention of ethylene oxide intraoperative anaphylaxis 113
Anxiety and depression in adolescents with asthma and in their parents. Is an increased basal cholinergic tone a possible further reason to explain the negative impact on asthma control? 113
World Allergy Organization anaphylaxis guidelines: Summary 113
Intraoperative anaphylaxis: verba volant, scripta manent! 113
COVID-19 lockdown, personal protective equipment, hyper-hygiene and allergy 113
A narrative review on asthma and pest sensitization (cockroach, mouse and rat allergens): a social issue besides the medical problem. 112
International consensus on (ICON) anaphylaxis 112
Hymenoptera Venom Immunotherapy: How to Safely Switch to the Same Venom From a Different Manufacturer 111
Drug hypersensitivity in clonal mast cell disorders: ENDA/EAACI position paper 111
High adherence to hymenoptera venom subcutaneous immunotherapy over a 5-year follow-up: A real-life experience 110
High long-term efficacy of venom immunotherapy after discontinuation 110
Hyposensitization therapy of Parietaria-sensitive patients with a tyrosine adsorbed allergoid, Pollinex Parietaria (Bencard Parietaria) 110
Congruence between international guidelines and mite specific immunotherapy prescribing practices 109
The VISYT trial: Venom Immunotherapy Safety and Tolerability with purified vs nonpurified extracts 108
The dilemma of the negative skin test reactors with a history of venom anaphylaxis: will this always be the case? 108
Lysozyme, a new allergen in donkey's milk 107
Ves v 5 can establish the diagnosis in patients without detectable specific IgE to wasp venom and a possible north-south difference in Api m 1 sensitization in Europe 107
A case of fatal biphasic anaphylaxis secondary to multiple stings: adrenalin and/or a longer observation time could have saved the patient? 106
Adherence to the rhinitis management plan of allergic rhinitis 106
The natural history and epidemiology of insect venom allergy: clinical implications 106
Anisakis hypersensitivity in Italy: prevalence and clinical features: a multicenter study. 106
Insect sting anoxic encephalopathy after stopping venom immunotherapy. 106
The additional values of microarray allergen assay in the management of polysensitized patients with respiratory allergy 105
Efficacy of mepolizumab in patients with concomitant severe eosinophilic asthma and severe chronic urticaria: an example of personalized medicine? 105
EAACI Molecular Allergology User's Guide 2.0. 104
Recommendations for the Use of Tryptase in the Diagnosis of Anaphylaxis and Clonal Mastcell Disorders 104
Clinical effectiveness of hymenoptera venom immunotherapy: a prospective observational multicenter study of the European academy of allergology and clinical immunology interest group on insect venom hypersensitivity 103
Sublingual immunotherapy with venom is not recommended for patients with Hymenoptera venom allergy 103
Platelet-activating factor acetylhydrolase: A biomarker in Hymenoptera venom allergy? 103
Totale 13.713
Salva come PNG Salva come JPEG
Categoria #
all - tutte 99.371
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 99.371
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022904 0 0 18 35 21 69 46 94 106 75 132 308
2022/20234.055 228 212 169 261 177 1.998 1 167 588 23 166 65
2023/20241.392 268 39 119 139 223 271 23 46 7 53 19 185
2024/20252.735 100 232 100 74 63 174 207 94 809 210 257 415
2025/20266.946 342 397 414 512 711 545 1.416 768 674 598 272 297
2026/20271.066 503 346 217 0 0 0 0 0 0 0 0 0
Totale 20.150